Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.

Date publication

novembre 2021

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Pr WESTEEL Virginie

Tous les auteurs :
Souquet PJ, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, Gervais R, Barlesi F, Pichon E, Zalcman G, Dumont P, Girard N, Poudenx M, Mazières J, Cadranel J, Debieuvre D, Dauba J, Langlais A, Morin F, Moro-Sibilot D, Westeel V, Pérol M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35051725

Résumé

Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditioned by response to cisplatin-gemcitabine (CG) with G continuation for patients with OR or switch to pemetrexed (P) for patients with SD as compared with a control arm based on the Paramount regimen.

Mots clés

Gemcitabine, Maintenance, Non-small cell lung cancer, Pemetrexed

Référence

Lung Cancer. 2021 Nov 30;164:84-90